PL3362449T3 - Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową - Google Patents
Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkowąInfo
- Publication number
- PL3362449T3 PL3362449T3 PL16781455T PL16781455T PL3362449T3 PL 3362449 T3 PL3362449 T3 PL 3362449T3 PL 16781455 T PL16781455 T PL 16781455T PL 16781455 T PL16781455 T PL 16781455T PL 3362449 T3 PL3362449 T3 PL 3362449T3
- Authority
- PL
- Poland
- Prior art keywords
- preventing
- disorders associated
- treating disorders
- sibiriline
- derivatives
- Prior art date
Links
- 230000001413 cellular effect Effects 0.000 title 1
- 230000021597 necroptosis Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biophysics (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306624 | 2015-10-13 | ||
| PCT/EP2016/074638 WO2017064217A1 (en) | 2015-10-13 | 2016-10-13 | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
| EP16781455.7A EP3362449B1 (en) | 2015-10-13 | 2016-10-13 | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3362449T3 true PL3362449T3 (pl) | 2021-12-13 |
Family
ID=54337712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16781455T PL3362449T3 (pl) | 2015-10-13 | 2016-10-13 | Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10426758B2 (pl) |
| EP (1) | EP3362449B1 (pl) |
| DK (1) | DK3362449T3 (pl) |
| ES (1) | ES2885474T3 (pl) |
| PL (1) | PL3362449T3 (pl) |
| WO (1) | WO2017064217A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3788045T2 (ro) | 2018-05-03 | 2023-09-30 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| HRP20231381T1 (hr) | 2018-05-03 | 2024-03-01 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| CN111978311B (zh) * | 2019-05-21 | 2024-05-31 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| JP7493586B2 (ja) | 2019-09-06 | 2024-05-31 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Rip1阻害化合物ならびにそれを作製および使用するための方法 |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| SI4055021T1 (sl) | 2019-11-07 | 2026-02-27 | Rigel Pharmaceuticals, Inc. | Heterociklične spojine, ki inhibirajo rip1 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| WO2022157392A1 (en) * | 2021-01-25 | 2022-07-28 | Seabelife | Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell death |
| AR125587A1 (es) | 2021-03-11 | 2023-08-02 | Rigel Pharmaceuticals Inc | Inhibidores heterocíclicos de la quinasa de rip1 |
| KR20250127084A (ko) | 2022-12-02 | 2025-08-26 | 시비라이프 | 조절된 괴사 억제제와 n-아세틸시스테인의 상승작용적 조합 |
| WO2025078659A1 (en) | 2023-10-12 | 2025-04-17 | Seabelife | Method and kit for inducing cell differentiation, and regulated necrotic cell death inhibitor for use for regenerating damaged tissues |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| EP2384753B1 (en) | 2003-08-29 | 2016-01-06 | The Brigham and Women's Hospital, Inc. | Hydantoin derivatives as inhibitors of cellular necrosis |
| US8148361B2 (en) * | 2006-11-10 | 2012-04-03 | Bristol-Myers Squibb Company | Kinase inhibitors |
| AU2011248175A1 (en) * | 2010-05-06 | 2012-10-25 | Merck Sharp & Dohme Corp. | Aza-Indole derivatives useful as modulators of FAAH |
| MX365640B (es) * | 2012-12-21 | 2019-06-10 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones. |
| TW201613916A (en) * | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| WO2017064216A1 (en) * | 2015-10-13 | 2017-04-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | N1- and n7-substituted sibiriline derivatives and their use as inhibitor of cellular necroptosis |
-
2016
- 2016-10-13 ES ES16781455T patent/ES2885474T3/es active Active
- 2016-10-13 PL PL16781455T patent/PL3362449T3/pl unknown
- 2016-10-13 US US15/768,388 patent/US10426758B2/en active Active
- 2016-10-13 DK DK16781455.7T patent/DK3362449T3/da active
- 2016-10-13 WO PCT/EP2016/074638 patent/WO2017064217A1/en not_active Ceased
- 2016-10-13 EP EP16781455.7A patent/EP3362449B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017064217A1 (en) | 2017-04-20 |
| US20180325876A1 (en) | 2018-11-15 |
| DK3362449T3 (da) | 2021-07-19 |
| ES2885474T3 (es) | 2021-12-13 |
| EP3362449B1 (en) | 2021-06-16 |
| EP3362449A1 (en) | 2018-08-22 |
| US10426758B2 (en) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3362449T3 (pl) | Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową | |
| IL256501B (en) | Causes, uses and methods of treating synuclein pathology | |
| IL256874B (en) | Immune checkpoint suppressors for use in the treatment of blood-borne cancers | |
| IL259570A (en) | Combined therapy and their uses and methods | |
| IL255780A (en) | Therapeutic combinations and methods for treating neoplasia | |
| IL253656A0 (en) | Mono- and polyazanephthalene modified histories and their use | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| IL252560B (en) | Heterocyclic derivatives and their uses | |
| GB2588261B (en) | Apparatus, use of the apparatus and arrangement | |
| GB201512733D0 (en) | Therapeutic agents for treating conditions associated with elevated GDF15 | |
| IL257820A (en) | Aminoglycosides for the treatment of genetic diseases | |
| IL271728A (en) | Materials, uses and treatment methods | |
| ZA201604611B (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| PT3166945T (pt) | Derivados de triazolopirimidinona ou de triazolopiridinona inovadores e utilização dos mesmos | |
| SG10201912843YA (en) | Sleep improving agent | |
| ZA202002526B (en) | New alcoxyamino derivatives for treating pain and pain related conditions | |
| PL3386988T3 (pl) | Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie | |
| PT3268356T (pt) | Compostos heterocíclicos e métodos para a sua utilização | |
| SG11201610349SA (en) | Dosing regimens for treating and/or preventing cerebral amyloidoses | |
| IL255012A0 (en) | Preparations and methods for treating skin conditions | |
| GB2545167B (en) | Cloches and use thereof | |
| GB201500278D0 (en) | Novel combination and use | |
| AU2014903677A0 (en) | Treating and/or preventing psoriasis |